The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Open accessAbstract
From the metal ions and metal compounds that are known to bind to DNA, many anticancer Pt(II) and Ru(II)/Ru(III) compounds are known to have ligand-exchange kinetics in the same order of magnitude as the division of tumor cells. The present article discusses this process in detail with special attention to cisplatin and related compounds and the cellular binding sites and processes of such compounds. Detailed platinated DNA structures are presented and discussed in light of the mechanistic studies of metal antitumor compounds. It is now known that platinum antitumor drugs eventually end up on the DNA. However, it remains a challenge to understand how (fast) they reach the DNA and how they are removed. The kinetics of ligand exchange around platinum appear to play a crucial role, and the possible role of other ligands as intermediates, especially those with S-donor sites, is of great interest. New types of Pt compounds with additional functionalities influencing DNA binding and kinetics are discussed in the context of steric and H-bonding properties. A comparison is made with more sterically crowded Ru complexes. The effects on activity and correlations with structural and kinetic properties are clues in understanding the biological activities of these classes of compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Self-citationUptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Barry, M. A., Behnke, C. A., & Eastman, A. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90733-2 · Cited by 867
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771
Self-citationPlatinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
DNA Cross-Linking Agents as Antitumor Drugs
Rajski, S. R., & Williams, R. M. (1998) · Chemical Reviews · doi:10.1021/cr9800199 · Cited by 592
Improved understanding in platinium antitumour chemistry
Reedijk, J. (1996) · Chemical Communications · doi:10.1039/cc9960000801 · Cited by 589
Self-citationCellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
Ohndorf, U.-M., Rould, M. A., He, Q., Pabo, C. O., & Lippard, S. J. (1999) · Nature · doi:10.1038/21460 · Cited by 565
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
Eastman, A., & Schulte, N. (1988) · Biochemistry · doi:10.1021/bi00413a022 · Cited by 312
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 280
The relevance of hydrogen bonding in the mechanism of action of platinum antitumor compounds
Reedijk, J. (1992) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)92433-2 · Cited by 247
Self-citationThe Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae
Lin, X., Okuda, T., Holzer, A., & Howell, S. B. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1154 · Cited by 232
DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
(2002) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(02)71040-4 · Cited by 230
Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity
Burger, K. N. J., Staffhorst, R. W. H. M., de Vijlder, H. C., Velinova, M. J., Bomans, P. H., Frederik, P. M., & de Kruijff, B. (2002) · Nature Medicine · doi:10.1038/nm0102-81 · Cited by 189
Ueber die Einwirkung des Ammoniaks auf Platinchlorür
Peyrone, M. (1844) · Justus Liebigs Annalen der Chemie · doi:10.1002/jlac.18440510102 · Cited by 168
Molecular aspects of resistance to antitumor platinum drugs
Brabec, V., & Kasparkova, J. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00047-x · Cited by 161
(1999) · CRC Press eBooks · doi:10.1201/9780203908457 · Cited by 147
Marzilli, L. G., Saad, J. S., Kuklenyik, Z., Keating, K. A., & Xu, Y. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0007915 · Cited by 113
Mello, J. A., Lippard, S. J., & Essigmann, J. M. (1995) · Biochemistry · doi:10.1021/bi00045a020 · Cited by 101
Deubel, D. V. (2002) · Journal of the American Chemical Society · doi:10.1021/ja012221q · Cited by 90
Testis-specific HMG-domain protein alters the responses of cells to cisplatin
Zamble, D. B., Mikata, Y., Eng, C. H., Sandman, K. E., & Lippard, S. J. (2002) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(02)00472-5 · Cited by 83
Zehnulová, J., Kašpárková, J., Farrell, N. P., & Brabec, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103118200 · Cited by 81
Cisplatin Complexes with Phosphatidylserine in Membranes
Speelmans, G., Staffhorst, R. W. H. M., Versluis, K., et al. (1997) · Biochemistry · doi:10.1021/bi9703047 · Cited by 69
The First Solid-Phase Synthesis of a Peptide-Tethered Platinum(II) Complex
Robillard, M. S., Valentijn, A. R. P. M., Meeuwenoord, N. J., MAREL, G. A. V. D., BOOM, J. H. V., & Reedijk, J. (2000) · Angewandte Chemie International Edition · Cited by 67
Self-citationYang, D., van Boom, S. S. G. E., Reedijk, J., BOOM, J. H. V., Farrell, N. P., & Wang, A. H. ‐. (1995) · Nature Structural Biology · doi:10.1038/nsb0795-577 · Cited by 56
Self-citationBioinorganic Chemistry: a Maturing Frontier
Lippard, S. J. (1993) · Science · doi:10.1126/science.8342037 · Cited by 51
Does resistance to apoptosis affect clinical response to antitumor drugs?
Borst, P., Borst, J. G., & Smets, L. A. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0187 · Cited by 40
A Platinum(IV) Complex Oxidizes Guanine to 8-Oxo-Guanine in DNA and RNA
Choi, S., Delaney, S., Orbai, L., Padgett, E. J., & Hakemian, A. S. (2001) · Inorganic Chemistry · doi:10.1021/ic015549t · Cited by 35
Popoff, S. C., Beck, D. J., & Rupp, W. D. (1987) · Mutation Research/DNA Repair Reports · doi:10.1016/0167-8817(87)90055-1 · Cited by 32
Nucleotide excision repair and anti-cancer chemotherapy
Reed, E. (1998) · Cytotechnology · doi:10.1023/a:1008016922425 · Cited by 29
A copper connection to the uptake of platinum anticancer drugs
Nitiss, J. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232574299 · Cited by 21
van Gijlswijk, R. P. M., Talman, E. G., Peekel, I., Bloem, J., van Velzen, M. A., Heetebrij, R. J., & Tanke, H. J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1352 · Cited by 20
Cited by
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Using coordination chemistry to design new medicines
Ronconi, L., & Sadler, P. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.11.017 · Cited by 608
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Metadata
- Authors
- Reedijk, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-03-24
- Volume
- 100
- Issue
- 7
- Pages
- 3611-3616
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2093282189
- Cited by
- 617
- References
- 43
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.